A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Apr 2009

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary)
Indications Bipolar depression; Bipolar disorders; Bipolar I disorders; Mania
Focus Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

10 Oct 2008 Quetiapine approved by US FDA supported by results from this study.
11 Apr 2008 The first presentation of results from this trial was on 11 Apr 2008 at the Eighth International Review of Bipolar Disorder (IRBD) Conference in Copenhagen, Denmark, reported in an AstraZeneca media release.
02 Nov 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight